Surmodics, Inc. recently announced early results from its PROWL registry study of a subset of 60 real-world patients with acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback